• Ocular Therapeutix recently highlighted its retinal pipeline at major ophthalmology meetings, where senior leaders discussed managing neovascular age-related macular degeneration and the role of tyrosine kinase inhibitors in treating diabetic retinal disease.
• Investors are closely watching these conference appearances for fresh colour on the phase 3 Axpaxli program, which sits at the centre of the company’s long-term growth plans.
• We’ll now explore how anticipated Axpaxli phase 3 updates from these meetings could influence Ocular Therapeutix’s existing investment narrative.

Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

Ocular Therapeutix Investment Narrative Recap

To own Ocular Therapeutix, you have to believe AXPAXLI can eventually justify today’s valuation despite ongoing losses and heavy dependence on a single late stage asset. The near term story still revolves around SOL-1 and SOL-R outcomes, and this week’s conference buzz does not materially change that core catalyst or the key risk that any clinical or regulatory setback could hit both sentiment and future revenue potential.

The most relevant recent development here is management’s clear plan, outlined in December 2025, to pursue an NDA for AXPAXLI based on year 1 SOL-1 data if results are supportive. Against that backdrop, the upcoming presentations on neovascular AMD and tyrosine kinase inhibitors are being watched less for incremental science and more for any hint of how close Ocular might be to that filing milestone and what it could mean for timelines and capital needs.

Yet beneath the excitement around Axpaxli updates, investors should also be aware of how quickly the story could change if superiority endpoints or safety outcomes begin to...

Ocular Therapeutix's narrative projects $287.1 million revenue and $57.1 million earnings by 2029.

Uncover how Ocular Therapeutix's forecasts yield a $26.00 fair value, a 196% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts take a much harsher view than consensus, assuming revenue of about US$82.2 million and only US$19.1 million in earnings by 2028, and arguing that Ocular’s heavy reliance on AXPAXLI’s trial outcomes makes those conference updates as much a potential warning sign as an upside catalyst.

Explore 5 other fair value estimates on Ocular Therapeutix - why the stock might be worth just $18.00!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.